Stocks Health care RLYB
NASDAQ · Health careRallybio Corp (RLYB)
Rallybio Corp brought in $646K of revenue over the twelve months to June 30, 2026, down 15.1% from a year earlier. Net income was $45.6M, a net margin of 7,051.2%. At June 30, 2026 it held $92.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Rallybio Corp does
Rallybio Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RLYB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $858K | -$9M | -$1.59 | n/a |
| 2024 | $636K | -$57.8M | -$10.61 | -$49.3M |
| 2023 | n/a | -$74.6M | -$14.68 | -$60.3M |
| 2022 | n/a | -$66.7M | -$16.67 | -$57.3M |
| 2021 | n/a | -$47M | -$14.68 | -$45.9M |
| 2021 | n/a | -$26.4M | -$12.13 | -$22.2M |
Latest SEC filings
What Rallybio Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026
- September 9, 2026
- August 26, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026Passive stake changed SCHEDULE 13G/A
- July 15, 2026
Questions about RLYB
What does Rallybio Corp do?
Rallybio Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RLYB.
Is Rallybio Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $45.6M on revenue of $646K, a net margin of 7,051.2%.
How much revenue does Rallybio Corp make?
Over the twelve months to June 30, 2026 Rallybio Corp reported revenue of $646K. That is 15.1% less than a year earlier.
When did Rallybio Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.
Similar companies
Follow RLYB
Get an email when Rallybio Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow RLYB: get an email when it filesWhere the numbers come from
Financial figures are the values Rallybio Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.